Literature DB >> 16271064

Management of bone and joint infections due to Staphylococcus aureus.

J S Davis1.   

Abstract

The clinical presentation, investigation, treatment and prevention of osteomyelitis, septic arthritis, and prosthetic joint infections due to Staphylococcus aureus are discussed in this review. It is difficult to make evidence-based recommendations on the treatment of these infections, as very little high quality clinical evidence exists. Experimental evidence, case series and published expert opinion are reviewed and used to suggest the preferred treatment options in each type of infection. A combination of prolonged intravenous antibiotic therapy and surgery is generally required for cure of S. aureus bone and joint infections. The current standard antibiotic therapy for these infections is an intravenous beta-lactam agent. Newer antibiotic approaches, such as use of fluoroquinolones and rifampicin are reviewed, as are newer surgical approaches, such as attempted salvage of infected prosthetic joints.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16271064     DOI: 10.1111/j.1444-0903.2005.00982.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  27 in total

1.  A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus.

Authors:  Brent W Wieland; Jodie R Marcantoni; Kerry M Bommarito; David K Warren; Jonas Marschall
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

2.  In vitro activities of daptomycin-, vancomycin-, and teicoplanin-loaded polymethylmethacrylate against methicillin-susceptible, methicillin-resistant, and vancomycin-intermediate strains of Staphylococcus aureus.

Authors:  Yuhan Chang; Wen-Chien Chen; Pang-Hsin Hsieh; Dave W Chen; Mel S Lee; Hsin-Nung Shih; Steve W N Ueng
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 3.  Current diagnostic tools for methicillin-resistant Staphylococcus aureus infections.

Authors:  Julianna Kurlenda; Mariusz Grinholc
Journal:  Mol Diagn Ther       Date:  2010-04-01       Impact factor: 4.074

4.  Staphylococcal IgM enzyme-linked immunosorbent assay for diagnosis of periprosthetic joint infections.

Authors:  Marco Artini; Carlo Romanò; Lamberto Manzoli; Gian Luca Scoarughi; Rosanna Papa; Enzo Meani; Lorenzo Drago; Laura Selan
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

5.  Osteomyelitis management: More art than science?

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-03       Impact factor: 2.471

6.  A controlled release of antibiotics from calcium phosphate-coated poly(lactic-co-glycolic acid) particles and their in vitro efficacy against Staphylococcus aureus biofilm.

Authors:  Kelsen Bastari; Mohamed Arshath; Zhi Hui Melissa Ng; Jia Hua Chia; Zhi Xian Daniel Yow; Barindra Sana; Meng Fong Cherine Tan; Sierin Lim; Say Chye Joachim Loo
Journal:  J Mater Sci Mater Med       Date:  2013-12-27       Impact factor: 3.896

7.  Outcome for invasive Staphylococcus aureus infections.

Authors:  G Jacobsson; E Gustafsson; R Andersson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-01       Impact factor: 3.267

8.  Blended Chitosan Paste for Infection Prevention: Preliminary and Preclinical Evaluations.

Authors:  Joel M Berretta; Jessica A Jennings; Harry S Courtney; Karen E Beenken; Mark S Smeltzer; Warren O Haggard
Journal:  Clin Orthop Relat Res       Date:  2017-07       Impact factor: 4.176

9.  Current management of prosthetic joint infections in adults: results of an Emerging Infections Network survey.

Authors:  Jonas Marschall; Michael A Lane; Susan E Beekmann; Philip M Polgreen; Hilary M Babcock
Journal:  Int J Antimicrob Agents       Date:  2013-01-09       Impact factor: 5.283

Review 10.  Daptomycin in bone and joint infections: a review of the literature.

Authors:  Dennis A K Rice; Luke Mendez-Vigo
Journal:  Arch Orthop Trauma Surg       Date:  2008-11-07       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.